

Springer Theses

Recognizing Outstanding Ph.D. Research

Andrew Giltrap

Total Synthesis of Natural Products with Antimicrobial Activity



Springer

Springer Theses

Recognizing Outstanding Ph.D. Research

Aims and Scope

The series “Springer Theses” brings together a selection of the very best Ph.D. theses from around the world and across the physical sciences. Nominated and endorsed by two recognized specialists, each published volume has been selected for its scientific excellence and the high impact of its contents for the pertinent field of research. For greater accessibility to non-specialists, the published versions include an extended introduction, as well as a foreword by the student’s supervisor explaining the special relevance of the work for the field. As a whole, the series will provide a valuable resource both for newcomers to the research fields described, and for other scientists seeking detailed background information on special questions. Finally, it provides an accredited documentation of the valuable contributions made by today’s younger generation of scientists.

Theses are accepted into the series by invited nomination only and must fulfill all of the following criteria

- They must be written in good English.
- The topic should fall within the confines of Chemistry, Physics, Earth Sciences, Engineering and related interdisciplinary fields such as Materials, Nanoscience, Chemical Engineering, Complex Systems and Biophysics.
- The work reported in the thesis must represent a significant scientific advance.
- If the thesis includes previously published material, permission to reproduce this must be gained from the respective copyright holder.
- They must have been examined and passed during the 12 months prior to nomination.
- Each thesis should include a foreword by the supervisor outlining the significance of its content.
- The theses should have a clearly defined structure including an introduction accessible to scientists not expert in that particular field.

More information about this series at <http://www.springer.com/series/8790>

Andrew Giltrap

Total Synthesis of Natural Products with Antimicrobial Activity

Doctoral Thesis accepted by
The University of Sydney, Sydney, Australia

Author

Dr. Andrew Giltrap
School of Chemistry
The University of Sydney
Sydney, NSW
Australia

Supervisor

Prof. Richard Payne
The University of Sydney
Sydney, NSW
Australia

ISSN 2190-5053

Springer Theses

ISBN 978-981-10-8805-6

<https://doi.org/10.1007/978-981-10-8806-3>

ISSN 2190-5061 (electronic)

ISBN 978-981-10-8806-3 (eBook)

Library of Congress Control Number: 2018934889

© Springer Nature Singapore Pte Ltd. 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. part of Springer Nature

The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Supervisor's Foreword

Natural products represent a unique source of biologically active molecules that have revolutionised modern medicine. One particularly significant class of natural products is nonribosomal peptides which include a number of clinically essential antibiotics such as penicillin and vancomycin. The ability to synthesise these peptide natural products represents the first step in the development of analogues and is essential in order to improve biological activity and medicinal chemical properties. The development of novel antibiotics with new mechanisms of action is desperately needed as bacteria are rapidly developing resistance to the currently used therapies.

The work described in this thesis represents the first total synthesis of two classes of important bioactive peptide natural products: teixobactin and the skyllamycins. The isolation and structure of teixobactin were first reported in 2015 and possess potent activity against a number of clinically relevant pathogenic bacteria, including methicillin-resistant *Staphylococcus aureus*. Using a solid-phase peptide synthesis approach, the total synthesis of teixobactin was successfully accomplished. Importantly, the synthetic natural product possessed potent activity against a number of gram-positive bacteria. This represented an important breakthrough in how to access teixobactin synthetically, and the technology developed is currently being applied to the generation of analogues.

The second part of this thesis involves the synthetic efforts towards the skyllamycins, a family of modified nonribosomal peptides with bacterial biofilm inhibitory activity. These natural products are highly complex and contain a number of synthetic challenges, including the unusual α -hydroxyglycine moiety. While these natural products were first reported in 2001 no total synthesis had been reported. This work describes the synthesis of four simplified analogues as well as the first total synthesis of a family of skyllamycin natural products. The final step of the total synthesis involved the concomitant cyclisation and formation of the unusual

α -hydroxyglycine. This work has laid the foundation for further synthetic and biosynthetic investigations into this unusual class of natural products, as well as the development of analogues with improved biological activity.

January 2018

Prof. Richard Payne

Abstract

Natural products are an essential source of many modern medicines. Examples of important natural products include the antibiotic penicillin, the anticancer drug taxol, the immunosuppressant cyclosporine and the antimalarial quinine. One significant class of bioactive natural products is nonribosomal peptides (NRPs), and two prototypical members of this class are the extremely important antibiotics, penicillin and vancomycin. Currently, bacterial resistance to antibiotics, including penicillin and vancomycin, is one of the most pressing global health issues. The need for new antibiotics with novel mechanisms of action is paramount. This thesis describes the total synthesis of the recently isolated antimicrobial NRPs teixobactin and skyllamycins A–C. Chapter 2 of this thesis describes the first total synthesis of teixobactin, a novel cyclic NRP antibiotic isolated in 2015. This was carried out *via* a solid-phase peptide synthesis (SPPS) strategy with a late-stage cyclisation reaction. The synthetic natural product possessed potent activity against a number of clinically relevant gram-positive bacterial pathogens. Chapters 3 and 4 describe investigations towards the total synthesis of skyllamycins A–C, a family of structurally complex cyclic NRPs. These natural products inhibit the growth of bacterial biofilms, a mechanism by which bacteria evade antibiotics. The most unusual feature of these natural products is the presence of an α -OH-glycine (Gly) moiety, which to date has only been found in one other linear peptide natural product. Chapter 3 details the synthesis of the non-proteinogenic amino acids present in the natural products and their incorporation into the synthesis of four skyllamycin analogues that omit the unusual α -OH-Gly residue. These analogues were analysed for their biofilm growth inhibition activity. Chapter 4 describes the completion of the first total synthesis of skyllamycins A–C. This was achieved through a SPPS strategy followed by a late-stage cyclisation and concomitant formation of the unusual α -OH-Gly residue in one step.

Parts of this thesis have been published in the following journal articles:

Giltrap, A. M.; Dowman, L. J.; Nagalingam, G.; Ochoa, J. L.; Linington, R. G.; Britton, W. J.; Payne, R. J. *Org. Lett.* **2016**, *18*, 2788–2791.

Giltrap, A. M.; Haeckl, F. P. J.; Kurita, K. L.; Linington, R. G.; Payne, R. J. *Chem. Eur. J.* **2017**, *23*, 15046–15049.

In addition to the statement above, in cases where I am not the corresponding author of the published item, permission to include the published material has been granted by the corresponding author.

Acknowledgements

To begin I would like to thank my supervisor Prof. Richard Payne for his unwavering support and guidance throughout my Ph.D. I have been a part of the Payne group in some capacity since 2010, and Rich has been a tremendous supervisor throughout this entire time. You have an enormous passion for science and you continually work very hard for the best of your students and for this I am extremely grateful.

Many thanks to all members of the Payne group past and present who have made the laboratory a great environment to work in. I have had a lot of fun during my Ph.D. In particular, thanks to Dr. Katie Terrett, my original mentor—thanks for everything you taught me. Thanks to Luke, it has been a privilege teaching you, and I have really enjoyed working on a number of projects with you. To the fellow Ph.D. students in my cohort, Dave and Nabs, it has been a pleasure doing a Ph.D. with you. We have made it! Thanks as well to the many past Payne group members who have become great friends, in particular James, Gaj, Nick, Bhav and Lukas. I would also like to thank the many friends I made in the other groups on level 5—you have made the Cornforth and Robinson laboratories a great place to work.

I would like to express my gratitude to the many members of the University of Sydney, School of Chemistry, who have made the work presented herein possible, in particular: Carlo Piscicelli, Bruce Dellit, Dr. Shane Wilkinson, Dr. Nick Proschogo, Dr. Cody Szczepina as well as my associate supervisor Associate Professor Chris McErlean. I would also like to thank Dr. Ian Luck for being a great boss in the NMR Facility. I have thoroughly enjoyed working for the facility and have learnt a lot in my time. I am also extremely grateful to the Australian Postgraduate Award and The University of Sydney Vice Chancellor's Scholarship for funding. Furthermore, I would especially like to acknowledge Dorothy Lamberton and John A. Lamberton Research Scholarship, for the generous financial support throughout my studies.

I would like to acknowledge my collaborators Dr. Gaya Nagalingham and Prof. Warwick Britton from the Centenary Institute for the TB expertise. I am also particularly grateful for the fruitful collaboration with Associate Professor Roger

Linington and the many hard-working members of his research group at both the University of California Santa Cruz and Simon Fraser University.

Finally, I would like to thank all of my family and friends for their support throughout my Ph.D. Mum and Dad, thanks for being extremely supportive in all things I have chosen to do and backing me enthusiastically at all opportunities. James and Kate, you have both been very supportive and I really appreciate the way you have kept me grounded at all times. Finally, Veronica you have been such a great support to me over my Ph.D. studies in the last nine and half years. You have been understanding when I have been working late or on weekends, encouraging when you know I have lots to get done, provided delicious baked goods that have made me loved by my laboratory mates and you are always keen for a G&T. Thanks for getting me through it.

Contents

1	Introduction	1
1.1	Natural Products as a Source of Drugs	1
1.1.1	Quinine—The First Anti-malarial	2
1.1.2	Artemisinin—From Chinese Herbal Medicine to Anti-malarial	2
1.1.3	Penicillin—From Mould to World Changing Antibiotic	3
1.1.4	The Current State of Affairs—Natural Products and Drug Development	5
1.2	The Problem of Antimicrobial Resistance	6
1.2.1	O’Neill Report	6
1.2.2	Mechanisms of Antibiotic Resistance	7
1.2.3	The Challenge of Antibiotic Drug Discovery	10
1.2.4	New Antibiotics Are Urgently Needed	12
1.3	Therapeutic Peptides	12
1.3.1	Peptides and Proteins	12
1.3.2	Therapeutic Peptides and NRPs	13
1.3.3	Vancomycin—A Game Changing Antibiotic	13
1.3.4	Daptomycin	15
1.4	Biosynthesis of NRPs	17
1.4.1	Generation of Amino Acid Diversity	18
1.4.2	Peptide Elongation and Release	19
1.4.3	Backbone Modification	23
1.5	Chemical Synthesis of Peptides	24
1.5.1	Solid-Phase Peptide Synthesis	25
1.5.2	Further Developments	26
1.6	Aims of Thesis	28
	References	29

2	Total Synthesis of Teixobactin	33
2.1	Discovery of Teixobactin	33
2.1.1	Initial Isolation and Structural Elucidation	33
2.1.2	Biosynthesis of Teixobactin	35
2.1.3	Antimicrobial Activity and Mechanism of Action	36
2.1.4	Media Attention	38
2.1.5	Synthesis of Arginine Analogue 34	38
2.2	Retrosynthesis of Teixobactin	40
2.2.1	Initial Retrosynthetic Approach	40
2.2.2	Considerations Regarding Cyclic Peptide Synthesis	40
2.2.3	Retrosynthesis of Cyclic Peptide 37	42
2.3	Synthesis of Enduracididine	42
2.3.1	Previous Syntheses of Enduracididine	43
2.3.2	Retrosynthesis of Protected <i>L</i> -allo-Enduracididine 46	43
2.3.3	Synthesis of Suitably Protected Enduracididine 58	44
2.4	Initial Efforts Towards Teixobactin	47
2.4.1	Initial Cyclisation Approaches by Mr. Luke Dowman	47
2.4.2	Optimisation of the Key On-resin Esterification Reaction	50
2.4.3	Towards the Synthesis of Cyclic Peptide 37	52
2.5	Total Synthesis of Teixobactin	54
2.5.1	Revised Retrosynthesis	54
2.5.2	Synthesis of Alloc-Ile-OH	54
2.5.3	Synthesis of Fmoc <i>D</i> -Thr(TES)-OH	56
2.5.4	Synthesis of Teixobactin	56
2.5.5	Characterisation of Teixobactin	59
2.5.6	Total Synthesis of Teixobactin by Li and Co-workers	64
2.6	Biological Activity	65
2.7	Conclusions and Future Directions	65
	References	67
3	Synthesis of Deshydroxy Skyllamycins A–C	71
3.1	Isolation of Skyllamycins A–C	71
3.1.1	Isolation and Initial Biological Analysis	72
3.1.2	Skyllamycins A–C—Biofilm Inhibition Studies	72
3.1.3	Full Stereochemical Assignment of Skyllamycins A–C	74
3.2	Biosynthesis of the Skyllamycins	75
3.2.1	Biosynthesis of Building Blocks	75
3.2.2	Assembly of the Peptide Backbone	77
3.2.3	β -Hydroxylation of Phe, <i>O</i> -Me-Tyr and Leu	78
3.2.4	Formation of α -OH-Glycine	79
3.3	Analogue Design	80

3.4	Retrosynthetic Analysis of Skyllamycin Analogues	81
3.5	Synthesis of Simplified Skyllamycin Analogue 115	83
3.5.1	Synthesis of Cinnamoyl Moiety 130	83
3.5.2	Solid Phase Assembly of 115	85
3.5.3	Biological Evaluation	86
3.6	Attempted Synthesis of Deshydroxy Skyllamycin B	89
3.6.1	Garner's Aldehyde—A Useful Starting Point for the Synthesis of β -OH Amino Acids	90
3.6.2	Synthesis of Suitably Protected β -OH-Leu 166	91
3.6.3	Synthesis of Suitably Protected β -OH-Phe 180	95
3.6.4	Synthesis of Suitably Protected β -OH- <i>O</i> -Me-Tyr 187	98
3.6.5	Attempted Assembly of Deshydroxy Skyllamycin B	101
3.7	Second Generation Synthesis of Deshydroxy Skyllamycin B	105
3.7.1	Revised Synthetic Strategy	105
3.7.2	Completion of the Synthesis of Deshydroxy Skyllamycin B	106
3.8	Synthesis of Deshydroxy Skyllamycin A and C	107
3.8.1	Synthesis of Reduced Cinnamoyl Moiety 131	109
3.8.2	Synthesis of Suitably Protected β -Me-Asp 212	110
3.8.3	Synthesis of Deshydroxy Skyllamycins A and C	112
3.9	Biological Evaluation	114
3.10	Conclusions and Future Directions	114
	References	115
4	Total Synthesis of Skyllamycins A–C	119
4.1	Previous Approaches to α -OH-Gly Moieties	119
4.1.1	Methods for the Synthesis of α -Functionalised-Gly Moieties	119
4.1.2	Studies Towards the Synthesis of Spergualin and 15-Deoxyspergualin	121
4.2	Retrosynthetic Analysis of Skyllamycins A–C	122
4.3	Synthesis of Skyllamycin B	124
4.3.1	Synthesis of Appropriately Protected β -OH-Phe 256	124
4.3.2	Synthesis of Linear Peptide 251	124
4.3.3	Oxidative Cleavage Reaction to Aldehyde 248	127
4.3.4	Initial Cyclisation Trial	129
4.3.5	Synthesis of Skyllamycin B	131
4.4	Synthesis of Skyllamycin A and C	134
4.4.1	Synthesis of Linear Peptides 250 and 252	134
4.4.2	Synthesis of Skyllamycin A	137
4.4.3	Synthesis of Skyllamycin C	137

4.5	Structural Analysis of Synthetic Skyllamycins A–C	140
4.5.1	Skyllamycin A	140
4.5.2	Skyllamycin B	143
4.5.3	Skyllamycin C	144
4.6	Biological Activity of Skyllamycin A–C	149
4.7	Conclusions and Future Directions	149
	References	150
5	Experimental	151
5.1	General Methods and Materials	151
5.2	Fmoc-SPPS General Protocols	152
5.3	Procedures and Analytical Data for Chapter 2	153
5.3.1	Synthesis of Goodman's Reagent 54	153
5.3.2	Synthesis of Fmoc-L- <i>allo</i> -Enduracididine (Cbz) ₂ -OH (58)	154
5.3.3	Synthesis of Protected Fmoc-D-Thr-OH	157
5.3.4	Synthesis of Alloc-L-Ile-OH (88)	160
5.3.5	Solid-Phase Synthesis of Teixobactin (28)	160
5.3.6	Antimicrobial Screening of Teixobactin (28)	166
5.4	General Procedures for Chapter 3	169
5.4.1	Fmoc-SPPS Protocols for Chapter 3	169
5.4.2	General Procedures for Modified Amino Acid Synthesis	169
5.4.3	General Procedures for Peptide Cyclisation	170
5.5	Procedures and Analytical Data for Chapter 3	171
5.5.1	Synthesis of Cinnamoyl Moiety 130	171
5.5.2	Synthesis of Reduced Cinnamoyl Moiety 131	173
5.5.3	Synthesis of Garner's Aldehyde (158) and (159)	176
5.5.4	Synthesis of Oxazolidine Protected Fmoc-β-OH-Leu-OH 166	177
5.5.5	Synthesis of Fmoc-β-OH-Phe-OH (180)	179
5.5.6	Synthesis of Oxazolidine Protected Fmoc-β-OH- <i>O</i> -Me-Tyr-OH (187)	181
5.5.7	Synthesis of Fmoc-β-Me-Asp(Ph _i Pr)-OH (212)	184
5.5.8	SPPS of Simplified Skyllamycin Analogue 115	187
5.5.9	Synthesis of Deshydroxy Skyllamycins A–C (116–118)	191
5.6	General Procedures for Chapter 4	201
5.6.1	Fmoc-SPPS Protocols for Chapter 4	201
5.6.2	General Procedures for the Synthesis of Skyllamycins A–C (101–103)	202
5.7	Procedures and Analytical Data Chapter 4	203
5.7.1	Synthesis of Oxazolidine Protected Fmoc-β-OH-Phe-OH (256)	203